Sildenafil for Women

Sildenafil blocks phosphodiesterase type 5, cyclic GMP builds up, smooth muscle relaxes and blood flows into erectile tissue. The label is explicit that the drug does nothing at all in the absence of sexual stimulation. Women have the same PDE5 enzyme and the same erectile tissue in the clitoris and vaginal wall, so the pharmacology carries across without much argument.

Whether extra blood flow changes what you actually feel is a separate question. Every trial in women has run straight into it.

The molecule is approved twice in the United States and neither approval is for female sexual function. As Viagra it is approved for erectile dysfunction, and as Revatio it is approved for pulmonary arterial hypertension in adults and in children aged 1 to 17, a use that has nothing to do with sex and does include women. For the pharmacology, interactions and dosing detail behind the approved male indication, see our erectile dysfunction sildenafil page rather than repeating it here.

The defining negative study randomized 577 estrogenized and 204 estrogen-deficient women to sildenafil 10 to 100 mg or placebo, and reported that differences in efficacy between sildenafil and placebo were not significant for any endpoint, whether rated by the woman or by her partner. The same paper flagged why the design struggled. Arousal disorder was the leading presenting complaint for only 46% and 50% of the two groups, so most of the enrolled women had walked in with a desire or orgasm problem instead. A crossover trial in 34 estrogenized postmenopausal women taking 50 mg found that sildenafil improved neither arousal nor orgasm, with any benefit confined to the subgroup that had measurably low vaginal blood flow at baseline. In 2004 Pfizer confirmed it would not seek a female license after about 3,000 women had been studied in placebo-controlled trials, calling the results inconclusive.

A Cochrane review of strategies for sexual dysfunction induced by antidepressant medication, covering 23 trials and 1,886 participants, concluded that for women it remains uncertain whether sildenafil is more effective than placebo. Read that scope carefully. It is a verdict on drug-induced dysfunction, not on sildenafil in women generally.

The one randomized trial that came out positive enrolled 98 premenopausal women whose depression was in remission on a serotonin reuptake inhibitor but who had developed sexual dysfunction, and gave 49 of them sildenafil 50 mg adjustable to 100 mg before sexual activity. Mean Clinical Global Impression sexual function score was 1.9 (95% CI 1.6 to 2.3) on sildenafil against 1.1 (0.8 to 1.5) on placebo, a difference of 0.8 (0.6 to 1.0), P=.001. Those are averages across a small trial, and individual results vary.

That study is doing narrow, specific work. It tested a drug-caused problem in women who were otherwise well, where the blockade is peripheral and a vasodilator has something to push against. Carrying baseline forward for the 22% who discontinued, the gap narrowed to 1.5 against 0.9, a difference of 0.6 (0.3 to 0.8), P=.03. Cochrane included this trial and still would not call the question settled in women. If your dysfunction started when your antidepressant did, that is the conversation worth having with whoever prescribes it.

Flibanserin is approved for women under 65 with acquired, generalized hypoactive sexual desire disorder, taken as 100 mg once daily at bedtime and discontinued after eight weeks if nothing improves. It carries a boxed warning for hypotension and syncope with alcohol, and it is contraindicated with moderate or strong CYP3A4 inhibitors and in hepatic impairment. A meta-analysis of 8 studies and 5,914 women found 0.49 additional satisfying sexual events per month (95% CI 0.32 to 0.67), with the quality of evidence graded very low.

Bremelanotide is approved for premenopausal women with the same diagnosis, injected 1.75 mg under the skin at least 45 minutes before anticipated activity, no more than once in 24 hours and not more than eight times a month. Nausea reached 40%, 13% needed an anti-emetic and 8% stopped the drug over it. The two phase 3 trials randomized 1,267 women and shifted the FSFI desire score by 0.35 against placebo. Neither is a large effect. Both are still larger than anything sildenafil produced in this population.

There is no established dose in women, because there is no approved indication to establish one against. Prescribers borrow the erectile dysfunction label, which sets 50 mg roughly one hour before sexual activity, allows anywhere from 30 minutes to 4 hours, permits adjustment down to 25 mg or up to 100 mg on response and tolerance, and caps frequency at once per day. Food is not a constraint. That is a male-derived regimen applied to a group it was never tested in.

The trials in women used the same range. Basson tested 10 to 100 mg and Nurnberg used 50 mg adjustable to 100 mg before sexual activity. Nobody has established how many attempts constitute a fair trial, what counts as a response, or when to stop. Whether any of this fits your situation is a call for the clinician writing the prescription, and a careful one will agree a trial length and a stopping point with you at the start instead of leaving the prescription running.

Sildenafil is contraindicated in anyone using organic nitrates or organic nitrites in any form, because it potentiates their hypotensive effect, and it is also contraindicated with the guanylate cyclase stimulator riociguat and in known hypersensitivity to sildenafil. The label lists headache, flushing, dyspepsia, abnormal vision, nasal congestion, back pain, myalgia, nausea, dizziness and rash among reactions reported at 2% or more. The SSRI-dysfunction trial reported headache, flushing and dyspepsia more often on sildenafil than on placebo in women too.

The label also carries warnings for cardiovascular events, prolonged erection, effects on the eye including sudden vision loss, sudden hearing loss, hypotension alongside alpha-blockers or antihypertensives, and effects on bleeding. None of that was characterized at scale in a female population, which is its own kind of unknown. Disclose every blood-pressure medication, every nitrate, any use of poppers and your cardiac history to whoever writes the prescription. This page is information and not medical advice.

The FDA's own position is that once a drug is approved, a healthcare provider generally may prescribe it for an unapproved use when they judge it medically appropriate, and that in that situation the FDA has not evaluated the drug for the unapproved use. That is the legal basis for every sildenafil prescription written for a woman in the United States. Legal is not the same as supported, and there is no approved labeling anywhere telling a prescriber how to dose it here, what to monitor, or when to stop.

An online intake form takes a few minutes and a licensed clinician reviews it before anything is dispensed. The speed is genuine and so is the gap it can paper over. A service that will hand you sildenafil for low desire without asking what your desire was like a year ago, what else you take, whether sex hurts, or how things sit with your partner is selling a molecule rather than working out a problem. Ask what the plan is if it does nothing.

A meta-analysis of 132 studies covering 2,505 women and 1,918 men found agreement between measured genital response and reported subjective arousal of r=.26 in women against r=.66 in men. That one number explains most of the failed trials.

Making the tissue respond does not reliably make you feel anything. Pfizer's own researchers said the same thing in 2004, noting that physiological response indicators were not predictive of whether a woman was distressed about her sexual life.

The PRESIDE survey of 31,581 US women found any sexual problem in 43.1% but a problem accompanied by personal distress in 12.0%, peaking at 14.8% between ages 45 and 64, and linked distressing problems to depression, anxiety, thyroid conditions, urinary incontinence and poor self-assessed health. The approved drugs make the same point from the regulatory side. Their indications explicitly exclude desire problems caused by a co-existing medical or psychiatric condition, by problems in the relationship, or by the effects of another medication. Those causes are common, and not one of them is a blood-flow problem.

The federal NADAC benchmark published on 2 September 2026 puts pharmacy acquisition cost at $0.10577 per 50 mg sildenafil tablet, $0.12762 per 100 mg tablet and $0.05101 per 20 mg tablet. Those are the prices a pharmacy pays to acquire the drug. What you are charged is a different number, and the spread between the two is where a telehealth price is made. Cash retail and subscription pricing vary widely by service and by state, so compare the total including any consultation fee rather than the per-dose figure a landing page leads with.

Creams, gels and troches marketed as female Viagra are a different matter. Compounded drugs are not FDA-approved, and the FDA does not verify the safety, effectiveness or quality of a compounded drug before it is marketed. A compounded drug is also not a generic, because a generic has to establish therapeutic equivalence and a compounded preparation never does. No topical sildenafil holds an approved indication in women, so you would be paying a premium for a formulation with less review behind it than the tablet that already failed the trials.

The best signal in a telehealth service here is a clinician who asks what changed and when, rather than one who confirms an order you already placed. Antidepressant timing, a new contraceptive, thyroid symptoms, pain with sex, sleep, and whether the problem is generalized or specific to one situation all change the answer. Both approved drugs restrict themselves to acquired, generalized desire disorder for that exact reason. A service that cannot reach a different diagnosis cannot offer a different treatment.

Ask three things before you pay. What are you being evaluated for? That is a different question from what is being sold. What happens if sildenafil does nothing, given that in women it usually did nothing in the trials. And who follows up, with what monitoring, on what schedule. A licensed clinician decides whether any medication suits you, and this page is information rather than medical advice. If the honest answer turns out to be that the evidence does not support this use, that is still an answer worth paying for.